Endocrine Abstracts

A new genetic animal model of type 2 diabetes, the Tsumura Suzuki Obese Diabetes (TSOD) mouse, has been developed in 1999. The TSOD mouse develops a moderate degree of obesity and diabetes. The aim of this study was to investigate the potential association of impairment of lipolysis and lipid metabolism on the development of obesity and diabetes in TSOD mice.Methods: Three month old TSOD and the age-matched control (TSNO: Tsumura Suzuki Non-Obesity) male...

Dehydroepiandrosterone (DHEA) has been suggested to have an anti-obesity effect; however, the mechanism underlying this effect remains unclear. The effect of DHEA on adipocytes opposes that of glucocorticoids, which potentiate adipogenesis. The key to the intracellular activation of glucocorticoids in adipocytes is 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which catalyses the production of active glucocorticoids (cortisol in humans and corticosterone in rod...

Objective: To investigate if the event of late-onset circulatory collapse (LCC) implicated in dysfunction of adrenal steroidgenesis due to impairment of adrenal remodeling in preterm infants.Methods: Eleven in the patient group (case) with clinical signs compatible with LCC diagnosis (hypotension, oliguria, and hyponatremia) and 11 in the control group (control) matched them for gestational age without such signs. Steroids in serum were separated and pur...

Excess glucocorticoids (GC) promote visceral obesity, hyperlipidemia and insulin resistance. The main regulators of intracellular GC levels are 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive GC into bioactive forms such as cortisol in humans and corticosterone in rodents. Therefore, the inhibition of 11β-HSD1 has considerable therapeutic potential for metabolic diseases including obesity and diabetes. Benzofran is a key structure in ...